Cargando…

Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch

Our aim was to explore the correlation between ultrasound attenuation parameter (UAP) and liver stiffness measurement (LSM) based on FibroTouch (China) and clinical features in patients with non-alcoholic fatty liver disease (NAFLD), so as to provide a certain basis for the clinical application of F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Yan, Liu, Lei, Yang, Jiayao, Zhou, Xiaoli, Teng, Xiaoli, Li, Yixi, Wan, Ying, Yang, Jian, Shi, Zhaohong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491815/ https://www.ncbi.nlm.nih.gov/pubmed/37684380 http://dx.doi.org/10.1038/s41598-023-41596-2

Ejemplares similares

Prospective Comparison of Transient Elastography Using Two Different Devices: Performance of FibroScan and FibroTouch
por: Serra, Joao Tiago, et al.
Publicado: (2020)

Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease
por: Ng, Ying Zhuang, et al.
Publicado: (2021)

Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
por: Qu, Ying, et al.
Publicado: (2021)

Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients
por: Deng, Hong, et al.
Publicado: (2016)

Diagnostic of FibroTouch and six serological models in assessing the degree of liver fibrosis among patients with chronic hepatic disease: A single-center retrospective study
por: Zuo, Zhongbao, et al.
Publicado: (2022)

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Ratziu, Vlad, et al.
Publicado: (2006)

Arrhythmogenicity of fibro-fatty infiltrations
por: De Coster, Tim, et al.
Publicado: (2018)

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
por: Shrestha, Rupesh, et al.
Publicado: (2021)

Fibro-fatty Degeneration in Hypertrophic Cardiomyopathy
por: Chaikriangkrai, Kongkiat, et al.
Publicado: (2018)

Fibro-fatty remodelling in arrhythmogenic cardiomyopathy
por: Kohela, Arwa, et al.
Publicado: (2022)

FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis
por: Vali, Yasaman, et al.
Publicado: (2021)

Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease
por: Van Dijk, Anne-Marieke, et al.
Publicado: (2021)

Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
por: Munteanu, Mona, et al.
Publicado: (2018)

The Efficacy of Anthropometric Indicators in Predicting Non-Alcoholic Fatty Liver Disease Using FibroScan(®) CAP Values among the Taiwanese Population
por: Lee, Meng-Szu, et al.
Publicado: (2023)

The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
por: Yilmaz, Yusuf, et al.
Publicado: (2023)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway
por: Yang, Jiayao, et al.
Publicado: (2020)

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
por: He, Tingshan, et al.
Publicado: (2020)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis
por: Hashemi, Seyed-Abbas, et al.
Publicado: (2016)

Hepatocyte nuclear factor 4α in the pathogenesis of non-alcoholic fatty liver disease
por: Pan, Xiaoli, et al.
Publicado: (2022)

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2021)

Fuzi-Lizhong Decoction Alleviates Nonalcoholic Fatty Liver Disease by Blocking TLR4/MyD88/TRAF6 Signaling
por: Yang, Jiayao, et al.
Publicado: (2022)

The Role of IL-6RA in UHMWPE Promotes Proliferation in Fibro-Like Synovial Cells
por: Pang, Xianlun, et al.
Publicado: (2018)

Myocyte Remodeling Due to Fibro-Fatty Infiltrations Influences Arrhythmogenicity
por: De Coster, Tim, et al.
Publicado: (2018)

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease
por: Li, Qiang, et al.
Publicado: (2020)

The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
por: Eris, Tansu, et al.
Publicado: (2023)

Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities
por: Miura, Kouichi, et al.
Publicado: (2022)

Diagnostic efficacy of FibroScan for liver inflammation in patients with chronic hepatitis B: a single-center study with 1185 liver biopsies as controls
por: Jiang, Kaiping, et al.
Publicado: (2022)

FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
por: Amernia, Behnaz, et al.
Publicado: (2021)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
por: Chaidez, Alexander, et al.
Publicado: (2022)

Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population
por: Li, Min-ran, et al.
Publicado: (2023)

Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges
por: Teng, Yu-Xian, et al.
Publicado: (2022)

Laboratory Tests, Liver Vessels Color Doppler Sonography, and FibroScan Findings in Patients with Nonalcoholic Fatty Liver Disease: An Observation Study
por: Alizadeh, Ahmad, et al.
Publicado: (2018)

The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
por: Fujii, Hideki, et al.
Publicado: (2021)

Ameloblastic fibro-odontoma
por: Surej Kumar, L.K., et al.
Publicado: (2014)

Circulation in Fibro-Sarcomas
por: Kini, M. G.
Publicado: (1942)

Implantation Fibro-Adenoma
Publicado: (1925)

Fibro Adenomata of the Breast
Publicado: (1908)

Cannot write session to /tmp/vufind_sessions/sess_aoeliqelf9r81ah79v2d6k9t75